DrugPatentWatch Database Preview
TENORMIN Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
When do Tenormin patents expire, and when can generic versions of Tenormin launch?
Tenormin is a drug marketed by Astrazeneca and Alvogen and is included in two NDAs.
The generic ingredient in TENORMIN is atenolol. There are thirty-four drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the atenolol profile page.
US ANDA Litigation and Generic Entry Outlook for Tenormin
A generic version of TENORMIN was launched as atenolol by ALVOGEN on December 13th, 2019.
Summary for TENORMIN


Recent Clinical Trials for TENORMIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
High Risk Obstetrical Consultants | Early Phase 1 |
University of Tennessee Graduate School of Medicine | Early Phase 1 |
BioHealthonomics Inc. | Phase 2 |
Pharmacology for TENORMIN
Drug Class | beta-Adrenergic Blocker |
Mechanism of Action | Adrenergic beta-Antagonists |
Synonyms for TENORMIN
( inverted question mark)-Atenolol |
(?)-Atenolol |
(+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide |
(+-)-Atenolol |
(+)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide |
(+/-)-4-(2-Hydroxy-3-[(1-methylethyl)amino]propoxy)benzeneacetamide |
(+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide |
(+/-)-Atenolol |
(1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide |
(A+/-)-Atenolol |
(r,s)-atenolol |
(RS)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide |
(RS)-Atenolol |
(y)-Atenolol |
1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol |
106020-65-9 |
122A687 |
2-(4-(2-hydroxy-3-(isopropylamino)propoxy) |
2-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide |
2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid |
2-(4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl)acetamide |
2-(4-{[(2S)-2-hydroxy-3-(propan-2-ylamino)propyl]oxy}phenyl)acetamide |
2-(4-{2-hydroxy-3-[(methylethyl)amino]propoxy}phenyl)acetamide |
2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide |
2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide |
2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide |
2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide |
2-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide |
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide |
2-{4-[2-Hydroxy-3-(isopropylamino)propoxy]-phenyl}acetamide |
2-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide |
2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide |
29122-68-7 |
4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide |
4-[2 -Hydroxy-3 -(isopropylamino)-propoxy]phenylacetamide |
4-[2'-Hydroxy-3'-(isopropylamino)-propoxy]phenylacetamide |
4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide |
60966-51-0 |
A 7655 |
AB00052208_16 |
AB00052208-13 |
AB00052208-15 |
AB0011597 |
AC-8245 |
AC1L1D99 |
AC1Q1QBX |
Acetamide, 2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)- |
Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl) |
Aircrit |
AKOS005111050 |
Alinor |
Altol |
AN-7253 |
Anselol |
Antipressan |
ANW-45215 |
API0001553 |
Apo-Atenolol |
ARONIS23884 |
Artrenolol |
Atcard |
Atcardil |
Atecard |
Atehexal |
Atenblock |
Atendol |
Atenet |
Ateni |
Atenil |
Atenol |
Atenol 1A pharma |
Atenol acis |
Atenol AL |
Atenol Atid |
Atenol Cophar |
Atenol ct |
Atenol Fecofar |
Atenol Gador |
Atenol Genericon |
Atenol GNR |
Atenol Heumann |
Atenol MSD |
Atenol NM Pharma |
Atenol Nordic |
Atenol PB |
Atenol Quesada |
Atenol Stada |
Atenol Tika |
Atenol Trom |
Atenol von ct |
Atenol-Mepha |
Atenol-ratiopharm |
Atenol-Wolff |
Atenolin |
atenolol |
Atenolol (JAN/USP) |
Atenolol (JP17/USP/INN) |
Atenolol [USAN:BAN:INN:JAN] |
Atenolol [USAN:INN:BAN:JAN] |
Atenolol [USAN:USP:INN:BAN:JAN] |
Atenolol 1.0 mg/ml in Acetonitrile |
Atenolol Bp |
Atenolol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material |
Atenolol, >=98% (TLC), powder |
Atenolol, 98% |
Atenolol, analytical reference material |
Atenolol, European Pharmacopoeia (EP) Reference Standard |
Atenolol, Pharmaceutical Secondary Standard; Certified Reference Material |
Atenolol, United States Pharmacopeia (USP) Reference Standard |
Atenolol,(S) |
Atenololum |
Atenololum [INN-Latin] |
Atenomel |
Atereal |
Aterol |
AX8005715 |
BB_SC-01519 |
BBC/163 |
BBL009276 |
BC201805 |
BCP12899 |
BDBM25753 |
Benzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)- |
BENZENEACETAMIDE, 4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-, (+-)- |
Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- |
benzeneacetamide, 4-[2'-hydroxy-3;-[(1-methylethyl)amino]propoxy]- |
Betablok |
Betacard |
Betasyn |
Betatop Ge |
BG0049 |
BIM-0050109.0001 |
Blocotenol |
Blokium |
BRD-A20239487-001-02-5 |
BRD-A20239487-001-15-7 |
BRN 2739235 |
BSPBio_002915 |
CA0145 |
Cardaxen |
Cardiopress |
CAS-29122-68-7 |
CCG-39010 |
CCRIS 4196 |
CHEBI:2904 |
CHEMBL24 |
Corotenol |
CPD000036768 |
CS-2927 |
CTK3J2163 |
Cuxanorm |
D00235 |
DB00335 |
DivK1c_000057 |
dl-Atenolol |
DSSTox_CID_2628 |
DSSTox_GSID_22628 |
DSSTox_RID_76663 |
DTXSID2022628 |
Duraatenolol |
duratenol |
EINECS 249-451-7 |
EINECS 262-544-7 |
EN300-119532 |
EU-0100121 |
Evitocor |
Farnormin |
Felo-Bits |
FT-0622499 |
FT-0693045 |
GEO-03413 |
GTPL548 |
Hipres |
HMS1569L13 |
HMS1921H09 |
HMS2090I19 |
HMS2092D19 |
HMS2233E06 |
HMS3259K08 |
HMS3260I04 |
HMS3266K13 |
HMS3369B14 |
HMS3369D20 |
HMS3369P20 |
HMS500C19 |
HSDB 6526 |
HY-17498 |
Hypoten |
I01-3572 |
Ibinolo |
ICI 66,082 |
ICI 66082 |
ICI-66082 |
IDI1_000057 |
InChI=1/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18) |
Internolol |
J10009 |
Jenatenol |
Juvental |
KB-222053 |
KB-47450 |
KB-62479 |
KBio1_000057 |
KBio2_001844 |
KBio2_004412 |
KBio2_006980 |
KBio3_002415 |
KBioGR_000790 |
KBioSS_001844 |
KS-00000XIG |
KS-000046IQ |
KS-5341 |
KSC492C6H |
L000116 |
Lo-ten |
Lopac0_000121 |
Loten |
Lotenal |
LP00121 |
LS-28557 |
LS-9707 |
MCULE-9148694071 |
METKIMKYRPQLGS-UHFFFAOYSA- |
METKIMKYRPQLGS-UHFFFAOYSA-N |
MFCD00057645 |
MLS000069622 |
MLS001066372 |
MLS001074163 |
MLS001304038 |
MolPort-001-792-717 |
MRF-0000571 |
Myocord |
NC00548 |
NCGC00015007-06 |
NCGC00015007-07 |
NCGC00015007-08 |
NCGC00015007-09 |
NCGC00015007-10 |
NCGC00015007-11 |
NCGC00015007-13 |
NCGC00024566-03 |
NCGC00024566-04 |
NCGC00024566-05 |
NCGC00024566-06 |
NCGC00024566-07 |
NCGC00255122-01 |
NCGC00260806-01 |
Neatenol |
NINDS_000057 |
Normalol |
Normiten |
Noten |
NSC-757832 |
NSC757832 |
Opera_ID_1283 |
Oprea1_448775 |
Oraday |
Ormidol |
Panapres |
Pharmakon1600-01501127 |
phenyl)acetamide |
Plenacor |
Premorine |
Prenolol |
Prenormine |
Prinorm |
Q-200656 |
RTR-012731 |
SAM002564193 |
SBB056998 |
SBI-0050109.P003 |
SC-19545 |
Scheinpharm Atenol |
SCHEMBL4362 |
Seles beta |
Selobloc |
Serten |
Servitenol |
SMR000036768 |
SPBio_001482 |
Spectrum_001364 |
SPECTRUM1501127 |
Spectrum2_001411 |
Spectrum3_001448 |
Spectrum4_000435 |
Spectrum5_001509 |
SR-01000000159 |
SR-01000000159-2 |
SR-01000000159-4 |
SR-01000000159-5 |
SR-01000000159-8 |
ST024754 |
ST2403914 |
Stermin |
STK528649 |
Tenidon |
Teno-basan |
Tenobloc |
Tenoblock |
Tenolol |
Tenoprin |
Tenoretic (Salt/Mix) |
Tenormin (TN) |
Tenormine |
Tenormine [French] |
Tensimin |
Tensotin |
Tox21_302426 |
Tox21_500121 |
TR-012731 |
Tredol |
Unibloc |
Uniloc |
Vascoten |
Vericordin |
Wesipin |
Xaten |
Z-0828 |
Z1541638518 |
ZX-AS004380 |
US Patents and Regulatory Information for TENORMIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | TENORMIN | atenolol | INJECTABLE;INJECTION | 019058-001 | Sep 13, 1989 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-004 | Apr 9, 1990 | AB | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TENORMIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-004 | Apr 9, 1990 | Start Trial | Start Trial |
Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |